Zacks Research Upgrades Precigen (NASDAQ:PGEN) to “Strong-Buy”

Precigen (NASDAQ:PGEN) was upgraded by investment analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a research note issued to investors on Wednesday,Zacks.com reports.

Several other equities research analysts have also recently issued reports on the company. Citigroup reissued an “outperform” rating on shares of Precigen in a research note on Thursday, May 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Precigen in a research note on Friday, July 17th. HC Wainwright increased their price target on Precigen from $14.00 to $18.00 and gave the stock a “buy” rating in a report on Wednesday. Wall Street Zen downgraded Precigen from a “buy” rating to a “hold” rating in a research report on Sunday, May 31st. Finally, Citizens Jmp boosted their price objective on shares of Precigen from $9.00 to $11.00 and gave the company a “market outperform” rating in a report on Thursday, May 14th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $14.50.

Precigen Stock Up 0.3%

Shares of NASDAQ PGEN opened at $6.91 on Wednesday. The company has a 50 day simple moving average of $5.17 and a 200-day simple moving average of $4.48. The company has a market capitalization of $2.46 billion, a P/E ratio of -6.64 and a beta of 1.02. The company has a debt-to-equity ratio of 2.15, a current ratio of 4.58 and a quick ratio of 4.12. Precigen has a 1 year low of $1.70 and a 1 year high of $7.23.

Precigen (NASDAQ:PGEN) last released its quarterly earnings results on Tuesday, August 4th. The biotechnology company reported $0.05 EPS for the quarter, beating the consensus estimate of ($0.01) by $0.06. Precigen had a negative net margin of 183.98% and a positive return on equity of 423.75%. The firm had revenue of $54.98 million for the quarter, compared to analyst estimates of $27.98 million. The business’s revenue was up 6322.7% on a year-over-year basis. On average, equities research analysts predict that Precigen will post -0.02 earnings per share for the current year.

Insider Activity at Precigen

In other Precigen news, CFO Harry Jr. Thomasian sold 100,000 shares of the company’s stock in a transaction on Friday, July 31st. The stock was sold at an average price of $6.06, for a total transaction of $606,000.00. Following the transaction, the chief financial officer directly owned 254,535 shares in the company, valued at $1,542,482.10. This represents a 28.21% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Rutul R. Shah sold 33,772 shares of the firm’s stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $6.50, for a total value of $219,518.00. Following the transaction, the chief operating officer owned 497,751 shares of the company’s stock, valued at approximately $3,235,381.50. This represents a 6.35% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 956,500 shares of company stock worth $5,248,371 over the last quarter. Company insiders own 41.40% of the company’s stock.

Institutional Investors Weigh In On Precigen

Several institutional investors and hedge funds have recently modified their holdings of PGEN. AQR Capital Management LLC boosted its holdings in Precigen by 216.9% during the 1st quarter. AQR Capital Management LLC now owns 63,179 shares of the biotechnology company’s stock valued at $94,000 after acquiring an additional 43,245 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Precigen by 12.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 81,610 shares of the biotechnology company’s stock worth $122,000 after purchasing an additional 9,043 shares during the period. Strs Ohio purchased a new stake in Precigen during the first quarter worth about $70,000. Geode Capital Management LLC increased its stake in Precigen by 7.7% during the second quarter. Geode Capital Management LLC now owns 3,749,182 shares of the biotechnology company’s stock worth $5,325,000 after purchasing an additional 269,580 shares during the period. Finally, Creative Planning lifted its position in shares of Precigen by 127.8% during the second quarter. Creative Planning now owns 94,291 shares of the biotechnology company’s stock worth $134,000 after purchasing an additional 52,901 shares in the last quarter. Hedge funds and other institutional investors own 33.51% of the company’s stock.

Key Stories Impacting Precigen

Here are the key news stories impacting Precigen this week:

• Positive Sentiment: Strong Q2 performance and profitability: Precigen reported that PAPZIMEOS revenue reached $53.1 million in the second quarter, roughly doubling sequentially. The company also achieved profitability, while earnings-call coverage highlighted a 145% increase in revenue. These results support the view that PAPZIMEOS is becoming a meaningful commercial product. Precigen Q2 2026 Earnings Call Highlights
• Positive Sentiment: Regulatory and commercial catalysts: FDA approval of PAPZIMEOS for recurrent respiratory papillomatosis, along with seven years of U.S. market exclusivity, strengthens the product’s revenue outlook. Potential European approval and expansion of Precigen’s AdenoVerse Immunotherapy platform—including PRGN-2009—could provide additional growth opportunities. Precigen Strong Buy and PAPZIMEOS Outlook
• Positive Sentiment: Analyst estimates moved higher: HC Wainwright reiterated its Buy rating and $18 price target, raising its FY2027 EPS forecast to $0.44 from $0.34. Estimates for Q4 2026 and each quarter of 2027 were also increased, while the FY2030 forecast rose to $1.49 from $1.44. These revisions signal greater confidence in the company’s earnings trajectory. HC Wainwright Reiterates Buy Rating for Precigen
• Neutral Sentiment: Unusually large options activity attracted attention, but the available report does not identify whether the transactions were bullish or bearish. Precigen Unusually Large Options Trading
• Negative Sentiment: One forecast was trimmed: HC Wainwright reduced its FY2028 EPS estimate slightly to $0.71 from $0.72, a minor offset to the broader upward revisions.

About Precigen

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.